leadf
logo-loader
viewEXMceuticals

EXMceuticals advances R&D operations in Portugal and its efforts to fight coronavirus

The bioscience company said it has applied for a P2020 research grant under the project name SkanABility for a proof-of-concept study of the biological activity of cannabinoids and terpenes in cosmeceutical applications

Cannabis flower
EXMceuticals also said it has recently submitted an application to the Portuguese government through the I&D COVID-19 initiative and has begun investigating the virucidal efficacy of cannabis and terpene molecules in combatting the coronavirus

EXMceuticals Inc (CSE:EXM) (FSE:A2PAW2) said it has made advancements in the research & development (R&D) operations at its facility in Lisbon, Portugal.

The bioscience firm, which specializes in unique cannabinoid formulations, said it has applied for a P2020 research grant under the project name SkanABility for a proof-of-concept study of the biological activity of cannabinoids and terpenes in cosmeceutical applications.

READ: EXMceuticals settles $4.6 million loan through share issuance

The project is seeking to demonstrate the commercial viability of cannabis compounds in cosmetic and aromatherapy products, as well as develop sustainable, functional packaging based on biodegradable cannabis materials such as fibers and waxes which will help to extend product shelf-life and preserve formulations and properties.

EXMceuticals noted that SkanABility will develop formulations for different types of cosmetics and aromatherapies such as acne face cleansers, anti-inflammatory and hypoallergenic treatments, and essential oils that the company plans to sell to industrial and pharmaceutical companies through a royalty-based business model.

The firm also said it has recently submitted an application to the Portuguese government through the I&D COVID-19 initiative and has begun investigating the virucidal efficacy of cannabis and terpene molecules in combatting the coronavirus.

Early indications suggest the molecules may inhibit the virus’s permanence on surfaces by attacking its cellular structure, which if proven effective could become key elements in commercial solutions sued to stop the spread of the virus, the company added.

EXMceuticals said it believes the molecules will help to reduce the spread of the illness and will be applicable in the disinfection of surfaces and goods, hand and body disinfection and coating social and surgical protective masks.

“COVID-19 is an inflection point in our history and has changed the way we view hygiene and cleanliness standards. It created ultra-high demand for cleaning products across industries, and consumers will seek out natural and effective alternatives, such as the ones being explored by EXM, that are less irritating to skin, less damaging to fabrics and surfaces, and the most sustainable for the environment”, the company concluded in a statement.

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

Quick facts: EXMceuticals

Price: 0.11 CAD

CSE:EXM
Market: CSE
Market Cap: $4.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

EXMceuticals now '100% focused on being a refining bioscience business in...

EXMceuticals Inc's (CSE:EXM) Jonathan Summers speaks to Proactive London's Katie Pilbeam about their cannabis research and development. Summers explains that the company has recently transitioned from being active in Africa to focusing their attentions solely onto Portugal. The company...

on 14/9/20

2 min read